Last week we put out a call to see what is happening with fingolimod, siponimod, ozanimod and ponesimod vaccine wise. Sad to say my phone has not been ringing and so far…..Radio Silence.
Is it rule number one from Pharma club? or just the studies are ongoing
With regard fingolimod we (royal we) have done our own studies. Fingolimod has surprisingly made a mediocre vaccine antibody response with BNT162b2 and AZD1222, which is surprising as there is no signal from being naturally infected. But fingo targets T cells too
However, it has not really appeared on the radar as the imods as they are not used in cancer and arthritis and so they have recieved no attention from the Joint Committee of Vaccines and Immunization.
However, fingo should perhaps be top of the MS list for third/booster dose. Researchers have been too busy going after anti-CD20 to take a look at the imods. There are hundreds of case reports on the influence of anti-CD20. However the imods would be the best candidates to be investigated because they can affect T and B cells. Surely there are enough people in trials for all of the manufcturers to know what is happening by now.
The big question for me is “What is happening to MSers taking Siponimod”…There will be more people out there taking this. What is your experience with being vaccinated? Did it work for you? What happened to your T and B cell responses? Will it be same a fingolimod or different? What vaccine did you get?
There were quite a few readers who “gave us a head-up” about their experience of boosters and anti-CD20
Siponimod has been on the market in the US the longest, what’s happening on the other side of the Pond?
The spies have informed me that there is an ECTRIMS report planned…I guess they haven’t heard of Twitter:-)
Assessing the immune response to SARS-CoV-2 mRNA vaccines in patients with secondary progressive multiple sclerosis treated with siponimod (AMA-VACC clinical trial): Tjalf Ziemssen, Tobias Bopp , Benedict Rauser, Benjamin Ettle, Marie Groth,
This Poster number 810
FYI This is trial NCT04792567 started in April 2021 finished by Jan 2022 looking at 60 siponimod with Moderna based on info in http://www.clinical trials.gov
There are also studies with ofatumumab
KYRIOS (COMB157GDE01; NCT04869358), and EMPISTOS
Disclaimer: Please note that the opinions expressed here are those of the author and do not reflect the positions of the Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust or Queen Mary Univeristy of London.